(Reuters) -Nektar Therapeutics said on Tuesday its experimental eczema drug had met the main goal of a mid-stage study.
In the 393-patient trial, drug candidate rezpegaldesleukin showed a reduction in the severity of eczema measured with a widely used index.
Eczema, also known as atopic dermatitis, is a chronic skin condition that causes inflammation, redness and intense itching.
Shares of the company were halted in premarket trading ahead of the trial data.
(Reporting by Puyaan Singh in Bengaluru; Editing by Shreya Biswas)
